DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Jung, Sungwon ^a   Kim, Seungchan ^a   Gale, Molly ^a   Cherni, Irene ^a   Fonseca, Rafael ^b   Carpten, John ^a   Salhia, Bodour ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DLC1 GENE; DNA METHYLATION; GENE; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; IGF1R GENE; IL17RB GENE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

CHROMOSOME ABERRATIONS; COMPUTATIONAL BIOLOGY; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC;

EID: 84871437541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052626     Document Type: Article

References (37)

1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, et al. (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23: 2210-2221.
2. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, et al. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472.
3. Herve AL, Florence M, Philippe M, Michel A, Thierry F, et al. (2011) Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 1893-1897.
4. Bergsagel PL, Kuehl WM, (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333-6338.
5. Cheung HH, Lee TL, Rennert OM, Chan WY, (2009) DNA methylation of cancer genome. Birth Defects Res C Embryo Today 87: 335-350.
6. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
7. Cheng X, Blumenthal RM, (2010) Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry 49: 2999-3008.
8. Esteller M, (2003) Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 532: 39-49.
9. Bird A, Taggart M, Frommer M, Miller OJ, Macleod D, (1985) A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 40: 91-99.
10. Cedar H, Bergman Y, (2012) Programming of DNA methylation patterns. Annual review of biochemistry 81: 97-117.
11. Han H, Cortez CC, Yang X, Nichols PW, Jones PA, et al. (2011) DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Human molecular genetics 20: 4299-4310.
12. Deaton AM, Bird A, (2011) CpG islands and the regulation of transcription. Genes & development 25: 1010-1022.
13. Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, et al. (2010) DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res 70: 6934-6944.
14. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, et al. (2009) Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nature biotechnology 27: 361-368.
15. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, et al. (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nature genetics 41: 178-186.
16. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, et al. (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 21: 529-534.
17. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, et al. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106: 296-303.
18. Jones PA, (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature reviews Genetics 13: 484-492.
19. Goodman JI, Counts JL, (1993) Hypomethylation of DNA: a possible nongenotoxic mechanism underlying the role of cell proliferation in carcinogenesis. Environmental health perspectives 101Suppl 5: 169-172.
20. Laurent L, Wong E, Li G, Huynh T, Tsirigos A, et al. (2010) Dynamic changes in the human methylome during differentiation. Genome research 20: 320-331.
21. Ogoshi K, Hashimoto S, Nakatani Y, Qu W, Oshima K, et al. (2011) Genome-wide profiling of DNA methylation in human cancer cells. Genomics 98: 280-287.
22. Song YF, Xu R, Zhang XH, Chen BB, Chen Q, et al. (2006) High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol 59: 947-951.
23. Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang XY, et al. (2009) DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 23: 383-390.
24. Chen W, Wu Y, Zhu J, Liu J, Tan S, et al. (2002) Methylation of p16 and p15 genes in multiple myeloma. Chin Med Sci J 17: 101-105.
25. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, et al. (2007) Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109: 1228-1232.
26. Guillerm G, Depil S, Wolowiec D, Quesnel B, (2003) Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica 88: 476-478.
27. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, et al. (2002) Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 118: 1034-1040.
28. Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, et al. (2009) Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J Lab Hematol.
29. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, et al. (2008) Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112: 2878-2885.
30. Chng WJ, Gualberto A, Fonseca R, (2006) IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 20: 174-176.
31. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, et al. (2010) Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 24: 1940-1950.
32. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K, (2009) The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Archives of physiology and biochemistry 115: 49-57.
33. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, et al. (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113: 4614-4626.
34. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, et al. (2009) A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. British journal of cancer 100: 366-369.
35. Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R, (2009) Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anti-cancer drugs 20: 259-266.
36. Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, et al. (2009) Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 3058-3067.
37. Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, et al. (2011) Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 25: 872-874.